Prostaglandin E2
Prostaglandin E2 (PGE2; CAS 363-24-6) is a lipid-derived autacoid that mediates diverse physiological processes via interaction with EP receptor subtypes EP1-4 (Ki values: 9.1, 4.9, 0.33, and 0.79 nM, respectively). EP receptors belong to the G protein-coupled receptor (GPCR) family, and their activation by PGE2 influences various signaling pathways, involved notably in immune regulation, gastrointestinal mucosal integrity, and cardiovascular homeostasis. PGE2 exhibits both pro- and anti-inflammatory effects, modulating functions of dendritic cells, macrophages, and lymphocytes. It is widely studied in inflammation research, gastrointestinal protection, and reproductive medicine applications.
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 352.47 |
| Cas No. | 363-24-6 |
| Formula | C20H32O5 |
| Solubility | ≥35.2 mg/mL in EtOH; insoluble in H2O; ≥42.8 mg/mL in DMSO |
| Chemical Name | (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid |
| SDF | Download SDF |
| Canonical SMILES | O[C@H](C1)[C@H](/C=C/[C@H](CCCCC)O)[C@@H](C/C=C\CCCC(O)=O)C1=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
HEK293 cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
N/A |
|
Applications |
In HEK293 cells, prostaglandin E2 bound the FP receptor with Ki value of 119 nM. PGE2 production in the kidney is critical for normal renal function by preserving renal blood flow and glomerular filtration rate in settings of physiological stress, modulating salt and water transport in the distal tubule, and stimulating renin release from the juxtaglomerular apparatus. |
| Clinical Trial [2]: | |
|
Disease models |
patients with rheumatic diseases |
|
Dosage form |
oral 1 mg three times daily or 0.33 mg three times daily |
|
Application |
In patients with rheumatic diseases, the indomethacin-induced bleeding was reduced to control level by concomitant oral PGE2 1 mg three times daily and was significantly reduced by 0.33 mg three times daily. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004 Aug;103(2):147-66. [2] Johansson C, Kollberg B. Clinical trials with prostaglandin E2. Prostaglandins. 1981;21 Suppl:161-4. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
